Harrow reports Q2 2026 results, reiterates full-year guidance, cites pipeline progress

Harrow, Inc. reported second quarter 2026 financial results on August 10, 2026, with quarterly revenue of $70.7 million, an increase of 60% sequentially and 11% year over year¹. The company said it reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA¹.

Several pipeline updates accompanied the results. For its G-MELT program, the FDA has granted Harrow a pre-NDA meeting, which the company said is a milestone toward finalizing its regulatory strategy ahead of an NDA submission¹. In the IHEEZO QUELL study, a randomized multi-center trial in patients undergoing intravitreal injections, topline data are expected in the fourth quarter of 2026¹. Harrow's Phase 3 trial of TRIESENCE for ocular inflammation and pain following cataract surgery is on track to fully enroll in 2026, with topline data expected in early 2027¹.

For NATACYN, patient enrollment began in an investigator-initiated study during the quarter, with topline data anticipated in the fourth quarter of 2026¹. On YOCHIL, Harrow said it finished its "End-of-Phase 2" discussion with regulators and is now folding that input into its planned Phase 3 design, according to the release.

On commercial products, IHEEZO brought in quarterly revenue of $15.6 million¹, with the company noting unit demand of 65,477 units, up 44% sequentially and 34% year-over-year, marking the product's highest unit volume quarter to date despite the April 1, 2026 loss of pass-through reimbursement status for cataract surgery¹.

On its balance sheet, Harrow reported cash and cash equivalents of $83.9 million as of June 30, 2026¹.